WHY ORBIS?



CAPABILITIES

EXTENDED RELEASE PARENTERALS
Extended release capability for small molecules, peptides, and proteins

PULSE RELEASE PARENTERALS
Pulse release capability for vaccines and special delivery mechanisms

INTRATYMPANIC DELIVERY
Delivery of therapeutic agents for treatment of otolaryngological diseases

ENTERIC-COATED ORAL POWDERS
A wide range of modified release options using format flexible powders

TASTE-MASKED ORAL POWDERS
Don’t sacrifice taste to get a dispersed solid oral dosage form

EXTENDED RELEASE ORAL SUSPENSIONS
Match extended release tablet performance in a suspension format
TECHNOLOGY

HOW IT WORKS
Precision Particle Fabrication® technology produces uniform microspheres and microcapsules with narrow size distribution and precise control over particle structure. Orbis’ technology is an elegant and robust solution…

SCALE & MANUFACTURING
Orbis’ platform technologies have been scaled from single nozzles to variations of multi-nozzles, then another order of magnitude by simply running multi-nozzles in parallel. Housed in Orbis’ Class 100,000 (ISO 8) production suite pictured below…
PIPELINE
Orbis Biosciences has a diverse product portfolio to leverage where Precision Particle Fabrication® technology differentiates products.
We are focused on creating novel oral and injectable therapeutics to improve compliance and patient satisfaction. Our products address clinical needs and are at various stages of development. Many of the products are based on strategic partnerships with pharmaceutical companies. Products developed internally are positioned for co-development and licensing arrangements.
PRESS RELEASES
Adare Pharmaceuticals, Inc. Acquires Orbis Biosciences
Kansas-based pharmaceutical technology company develops customized formulations and intellectual propertyDeal includes platforms that can be dosed in oral, injectable and otic (ear) formulationsAcquisition expands Adare’s [...]
Orbis Biosciences Completes Successful Phase I Clinical Trial
LENEXA, KS – May 19, 2017 – Orbis Biosciences, Inc., is proud to announce the completion of its first-in-human clinical trial with ORB-101, its [...]
Orbis Biosciences Named Finalist in the Fierce Innovation Awards
LENEXA, KS – December 8, 2017 – Orbis Biosciences, Inc., is a finalist for the FierceBiotech and FiercePharma (Fierce) Innovation Awards. Orbis Biosciences’ submission [...]